Episode Details

Moderna’s mRNA flu vaccine, mFlusiva, could revolutionize flu prevention—especially for seniors—by slashing development time and adapting faster to mutating strains. After a brief FDA pause over study design, the agency now reviews data showing antibody levels rivaling high-dose shots, though gaps remain for frail elderly and immunocompromised patients. This pivotal moment could reshape flu season defense as winter looms.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/cc0c8d25176035f1